Certolizumab pegol

Drug Profile

Certolizumab pegol

Alternative Names: CDP-870; Cimzia; CIMZIA AutoClicks Prefilled Pen; CZP; PHA-738144; Simziya

Latest Information Update: 09 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator UCB
  • Developer Astellas Pharma; Dermira; UCB; University of Southampton
  • Class Anti-inflammatories; Antirheumatics; Fab fragments; Monoclonal antibodies; Polyethylene glycols
  • Mechanism of Action Immunosuppressants; Tumour necrosis factor alpha inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Ankylosing spondylitis; Crohn's disease; Psoriatic arthritis; Rheumatoid arthritis; Spondylitis
  • Preregistration Plaque psoriasis
  • Phase III Interstitial cystitis; Juvenile rheumatoid arthritis
  • Discontinued Cognition disorders

Most Recent Events

  • 06 Nov 2017 Dermira agrees to terminate its licence with UCB for certolizumab pegol development in USA, Canada and European Union and marketing in USA and Canada
  • 20 Oct 2017 US FDA accepts sBLA for certolizumab pegol for Plaque psoriasis for review
  • 04 Oct 2017 Phase-II clinical trials in Ankylosing spondylitis (Treatment-experienced) in Moldova (SC)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top